Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex

Ning Liang, Chi Zhang, Patricia Dill, Ganna Panasyuk, Delphine Pion, Vonda Koka, Morgan Gallazzini, Eric N. Olson, Hilaire Lam, Elizabeth P. Henske, Zheng Dong, Udayan Apte, Nicolas Pallet, Randy L. Johnson, Fabiola Terzi, David J. Kwiatkowski, Jean Yves Scoazec, Guido Martignoni, Mario Pende

Research output: Contribution to journalArticlepeer-review

150 Scopus citations


Genetic studies have shown that the tuberous sclerosis complex (TSC) 1-TSC2-mammalian target of Rapamycin (mTOR) and the Hippo-Yes-associated protein 1 (YAP) pathways are master regulators of organ size, which are often involved in tumorigenesis. The crosstalk between these signal transduction pathways in coordinating environmental cues, such as nutritional status and mechanical constraints, is crucial for tissue growth. Whether and how mTOR regulates YAP remains elusive. Here we describe a novel mouse model of TSC which develops renal mesenchymal lesions recapitulating human perivascular epithelioid cell tumors (PEComas) from patients with TSC. We identify that YAP is up-regulated by mTOR in mouse and human PEComas. YAP inhibition blunts abnormal proliferation and induces apoptosis of TSC1-TSC2-deficient cells, both in culture and in mosaic Tsc1 mutant mice. We further delineate that YAP accumulation in TSC1/TSC2-deficient cells is due to impaired degradation of the protein by the autophagosome/lysosome system. Thus, the regulation of YAP by mTOR and autophagy is a novel mechanism of growth control, matching YAP activity with nutrient availability under growth-permissive conditions. YAP may serve as a potential therapeutic target for TSC and other diseases with dysregulated mTOR activity.

Original languageEnglish (US)
Pages (from-to)2249-2263
Number of pages15
JournalJournal of Experimental Medicine
Issue number11
StatePublished - 2014

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex'. Together they form a unique fingerprint.

Cite this